Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon And Zentiva Hail Milestone Liraglutide Approval In UK

Partners Plan For ‘Expeditious’ Launch After Claiming Leading Position On GLP-1

Executive Summary

Biocon and Zentiva have celebrated the “first generic liraglutide approved in a major regulated/ICH market” after an endorsement from the UK’s MHRA.

You may also be interested in...



Biocon And Juno Partner On Liraglutide In Canada

Biocon has announced a partnership with Juno Pharmaceuticals to market its liraglutide diabetes treatment in Canada, where the firms see a market worth as much as $100m.

First Interchangeable Biosimilar Launched In US

Viatris and Biocon have introduced their interchangeable Semglee insulin glargine biosimilar in the US, along with an unbranded interchangeable version, marking the first ever launch of an interchangeable biosimilar. The non-interchangeable version is expected to be phased out rapidly.

Boehringer’s Slashed Cyltezo Salesforce Reflects Struggles For US Humira Biosimilars

Boehringer Ingelheim’s decision not only reflects the company’s difficulties in gaining traction for the first interchangeable version of adalimumab, but also the wider problems for Humira biosimilars in the US.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153405

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel